CAT #: 40880098
LymphoTrack® B-Cell Low Positive Control
Minimal Residual Disease (MRD) testing is a valuable tool that allows investigators to study and monitor multiple myeloma (MM) , chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and other hematologic diseases. Recent treatment advances have led to significantly increased clinical response and overall survival, but ultimately most subjects will relapse, driving the need for highly sensitive MRD monitoring. The unparalleled sensitivity of NGS-based MRD testing enables earlier detection of relapse compared to conventional methods and may provide insights to optimize treatment strategies1.
In addition to the need for more sensitive tracking, it is clear that standardized methods are needed. Currently, MRD methods are highly subjective and recommendations are often based on consensus expert-shared knowledge and experience, not on a validated, objective method.
Once specific rearrangements have been identified, LymphoTrack assays can be used with LymphoQuant and LymphoTrack Low Positive Controls to track these clonotype populations to a sensitivity as low as 10-6.
This product is sold FOR RESEARCH USE ONLY; not for use in diagnostic procedures.
LymphoTrack® B-cell Low Positive Control can be used as a control for:
Gene Rearrangements: IGH, IGK
Chromosome Translocations: n/c
©2019 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.
FOR RESEARCH USE ONLY; not for use in diagnostic procedures.
1Cheng et al. J Hematol Onc. (2018) 11:105.